Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
12.27
-0.15 (-1.21%)
Aug 14, 2026, 4:00 PM EDT - Market closed
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 80.71B INR in the quarter ending June 30, 2026, a decrease of -5.56%. This brings the company's revenue in the last twelve months to 331.19B, down -0.92% year-over-year. In the fiscal year ending March 31, 2026, Dr. Reddy's Laboratories had annual revenue of 335.93B with 3.19% growth.
Revenue (ttm)
331.19B INR
Revenue Growth
-0.92%
P/S Ratio
2.99
Revenue / Employee
12,031,315 INR
Employees
27,527
Market Cap
10.47B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 335.93B | 10.40B | 3.19% |
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
| Mar 31, 2019 | 153.85B | 11.82B | 8.32% |
| Mar 31, 2018 | 142.03B | 1.22B | 0.87% |
| Mar 31, 2017 | 140.81B | -13.90B | -8.98% |
| Mar 31, 2016 | 154.71B | 6.52B | 4.40% |
| Mar 31, 2015 | 148.19B | 16.02B | 12.12% |
| Mar 31, 2014 | 132.17B | 15.90B | 13.68% |
| Mar 31, 2013 | 116.27B | 19.53B | 20.19% |
| Mar 31, 2012 | 96.74B | 22.04B | 29.51% |
| Mar 31, 2011 | 74.69B | 4.42B | 6.28% |
| Mar 31, 2010 | 70.28B | 836.00M | 1.20% |
| Mar 31, 2009 | 69.44B | 19.44B | 38.87% |
| Mar 31, 2008 | 50.01B | -79.27B | -61.32% |
| Mar 31, 2007 | 129.28B | 80.94B | 167.42% |
| Mar 31, 2006 | 48.34B | 9.70B | 25.10% |
| Mar 31, 2005 | 38.65B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viatris | 14.74B |
| Elanco Animal Health | 5.02B |
| Neurocrine Biosciences | 3.37B |
| United Therapeutics | 3.15B |
| Amneal Pharmaceuticals | 3.12B |
| Hims & Hers Health | 2.58B |
| Alkermes | 1.67B |
| Lantheus Holdings | 1.56B |
RDY News
- 1 day ago - RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
- 9 days ago - DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - GlobeNewsWire
- 9 days ago - Laurus Labs surges past Rs 1 lakh crore MCAP & biggies like Dr Reddy’s - The Times of India
- 11 days ago - Dr. Reddy's Launches First-to-Market Generic Sugammadex Injection In The U.S - Nasdaq
- 11 days ago - Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States - Business Wire
- 11 days ago - Dr Reddy’s registers PD-1 inhibitor for rare head and neck cancer in South Africa - The Times of India
- 13 days ago - Dr Reddy’s gets USFDA nod for Rituximab biosimilar - The Times of India
- 14 days ago - Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky - PRNewsWire